retatrutide type 2 diabetes trial results Weight loss with as compared to licenced obesity The numbers from Lilly's Phase

(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers

Send questions or comments to [email protected]

The key is choosing a product made from 100% macadamias without added seed oils or sugars - those additions undermine the very metabolic benefits youre after

Effect of age on blood glucose and plasma insulin, glucagon, ghrelin, CCK, GIP, and GLP-1 responses to whey protein ingestion

Lifestyle changes are key when it comes to naturally boosting GLP-1but sometimes your body needs a little extra support